This article uses bare URLs, which are uninformative and vulnerable to link rot. Please consider converting them to full citations to ensure the article remains verifiable and maintains a consistent citation style. Several templates and tools are available to assist in formatting, such as reFill ( documentation) and Citation bot ( documentation). (September 2022) ( Learn how and when to remove this template message)

Stephen Kevin Burley is a British-born scientist, naturalized in both Canada and the United States, specializing in oncology and structural biology. He is a University Professor and Henry Rutgers Chair at Rutgers, The State University of New Jersey. Burley directs the RCSB Protein Data Bank (a member of the Worldwide Protein Data Bank), the Center for Integrative Proteomics Research, and the Institute for Quantitative Biomedicine.

Career

Burley has a Bachelor in physics from the University of Western Ontario ^[1] and a D.Phil from Oxford University, England in Molecular Biophysics as a Rhodes scholar. ^[2] Burley has an M.D. from Harvard Medical School.

He worked with Gregory A. Petsko and William N. Lipscomb at MIT and Harvard. He was faculty at Howard Hughes Medical Institute and Rockefeller University. Burley co-founded Prospect Genomics, Inc, ^[3] a computational genomics pharma. He was Chief Scientific Officer of SGX Pharmaceuticals after it acquired Prospect. SGX was in turn merged with Eli Lilly in 2008 where Burley was a Distinguished Lilly Research Scholar in Lilly Research Laboratories ^[4]

In 2012 Burley joined Rutgers ^[5] as Director of the Center for Integrative Proteomics Research and became director of the RCSB PDB (US regional data center for the worldwide PDB) in 2014, succeeding Prof. Helen Berman ^[6]

He is a member of the Editorial Board for Oncogene. ^[7]

Honors and awards

• Fellow of the Royal Society of Canada (elected 1995)

References